Venous thromboembolic disease: Clinical practice guidelines in Oncology™

Lawrence D. Wagman; Melissa F. Baird; Charles L. Bennett; Paula L. Bockenstedt; Spero R. Cataland; John Fanikos; Patrick F. Fogarty; Samuel Z. Goldhaber; Tejpal S. Grover; William Haire; Hani Hassoun; Mohammad Jahanzeb; Lawrence L. Leung; Michael L. Linenberger; Michael M. Millenson; Thomas L. Ortel; Riad Salem; Judy L. Smith; Michael B. Streiff

doi:10.6004/jnccn.2006.0071

Venous thromboembolic disease: Clinical practice guidelines in Oncology™

Lawrence D. Wagman, Melissa F. Baird, Charles L. Bennett, Paula L. Bockenstedt, Spero R. Cataland, John Fanikos, Patrick F. Fogarty, Samuel Z. Goldhaber, Tejpal S. Grover, William Haire, Hani Hassoun, Mohammad Jahanzeb, Lawrence L. Leung, Michael L. Linenberger, Michael M. Millenson, Thomas L. Ortel, Riad Salem, Judy L. Smith, Michael B. Streiff

School of Medicine

Research output: Contribution to journal › Review article › peer-review

45 Scopus citations

Abstract

Recognizing the increased risk of VTE in cancer patients is the first step in preventing the occurrence of VTE and promptly identifying the disease in cancer patients. The NCCN panel recommends VTE thromboprophylaxis for all hospitalized patients with cancer who do not have contraindications to such therapy, and the panel also emphasizes that an increased level of clinical suspicion of VTE should be maintained for cancer patients. Careful evaluation and follow-up of cancer patients in whom VTE is suspected and prompt treatment and follow-up for patients diagnosed with VTE is recommended after the cancer status of the patient and the risks and benefits of treatment are considered.

Original language	English (US)
Pages (from-to)	838-869
Number of pages	32
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	4
Issue number	9
DOIs	https://doi.org/10.6004/jnccn.2006.0071
State	Published - Oct 2006

Keywords

Anticoagulation
Cancer
Deep venous thrombosis
Heparin
NCCN Clinical Practice Guidelines
Pulmonary embolism
Venous thromboembolism

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2006.0071

Cite this

Wagman, L. D., Baird, M. F., Bennett, C. L., Bockenstedt, P. L., Cataland, S. R., Fanikos, J., Fogarty, P. F., Goldhaber, S. Z., Grover, T. S., Haire, W., Hassoun, H., Jahanzeb, M., Leung, L. L., Linenberger, M. L., Millenson, M. M., Ortel, T. L., Salem, R., Smith, J. L., & Streiff, M. B. (2006). Venous thromboembolic disease: Clinical practice guidelines in Oncology™. JNCCN Journal of the National Comprehensive Cancer Network, 4(9), 838-869. https://doi.org/10.6004/jnccn.2006.0071

Wagman, LD, Baird, MF, Bennett, CL, Bockenstedt, PL, Cataland, SR, Fanikos, J, Fogarty, PF, Goldhaber, SZ, Grover, TS, Haire, W, Hassoun, H, Jahanzeb, M, Leung, LL, Linenberger, ML, Millenson, MM, Ortel, TL, Salem, R, Smith, JL & Streiff, MB 2006, 'Venous thromboembolic disease: Clinical practice guidelines in Oncology™', JNCCN Journal of the National Comprehensive Cancer Network, vol. 4, no. 9, pp. 838-869. https://doi.org/10.6004/jnccn.2006.0071

@article{d2e749ac4e7447f6aa961f15c359071a,

title = "Venous thromboembolic disease: Clinical practice guidelines in Oncology{\texttrademark}",

abstract = "Recognizing the increased risk of VTE in cancer patients is the first step in preventing the occurrence of VTE and promptly identifying the disease in cancer patients. The NCCN panel recommends VTE thromboprophylaxis for all hospitalized patients with cancer who do not have contraindications to such therapy, and the panel also emphasizes that an increased level of clinical suspicion of VTE should be maintained for cancer patients. Careful evaluation and follow-up of cancer patients in whom VTE is suspected and prompt treatment and follow-up for patients diagnosed with VTE is recommended after the cancer status of the patient and the risks and benefits of treatment are considered.",

keywords = "Anticoagulation, Cancer, Deep venous thrombosis, Heparin, NCCN Clinical Practice Guidelines, Pulmonary embolism, Venous thromboembolism",

author = "Wagman, {Lawrence D.} and Baird, {Melissa F.} and Bennett, {Charles L.} and Bockenstedt, {Paula L.} and Cataland, {Spero R.} and John Fanikos and Fogarty, {Patrick F.} and Goldhaber, {Samuel Z.} and Grover, {Tejpal S.} and William Haire and Hani Hassoun and Mohammad Jahanzeb and Leung, {Lawrence L.} and Linenberger, {Michael L.} and Millenson, {Michael M.} and Ortel, {Thomas L.} and Riad Salem and Smith, {Judy L.} and Streiff, {Michael B.}",

year = "2006",

month = oct,

doi = "10.6004/jnccn.2006.0071",

language = "English (US)",

volume = "4",

pages = "838--869",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "9",

}

TY - JOUR

T1 - Venous thromboembolic disease

T2 - Clinical practice guidelines in Oncology™

AU - Wagman, Lawrence D.

AU - Baird, Melissa F.

AU - Bennett, Charles L.

AU - Bockenstedt, Paula L.

AU - Cataland, Spero R.

AU - Fanikos, John

AU - Fogarty, Patrick F.

AU - Goldhaber, Samuel Z.

AU - Grover, Tejpal S.

AU - Haire, William

AU - Hassoun, Hani

AU - Jahanzeb, Mohammad

AU - Leung, Lawrence L.

AU - Linenberger, Michael L.

AU - Millenson, Michael M.

AU - Ortel, Thomas L.

AU - Salem, Riad

AU - Smith, Judy L.

AU - Streiff, Michael B.

PY - 2006/10

Y1 - 2006/10

N2 - Recognizing the increased risk of VTE in cancer patients is the first step in preventing the occurrence of VTE and promptly identifying the disease in cancer patients. The NCCN panel recommends VTE thromboprophylaxis for all hospitalized patients with cancer who do not have contraindications to such therapy, and the panel also emphasizes that an increased level of clinical suspicion of VTE should be maintained for cancer patients. Careful evaluation and follow-up of cancer patients in whom VTE is suspected and prompt treatment and follow-up for patients diagnosed with VTE is recommended after the cancer status of the patient and the risks and benefits of treatment are considered.

AB - Recognizing the increased risk of VTE in cancer patients is the first step in preventing the occurrence of VTE and promptly identifying the disease in cancer patients. The NCCN panel recommends VTE thromboprophylaxis for all hospitalized patients with cancer who do not have contraindications to such therapy, and the panel also emphasizes that an increased level of clinical suspicion of VTE should be maintained for cancer patients. Careful evaluation and follow-up of cancer patients in whom VTE is suspected and prompt treatment and follow-up for patients diagnosed with VTE is recommended after the cancer status of the patient and the risks and benefits of treatment are considered.

KW - Anticoagulation

KW - Cancer

KW - Deep venous thrombosis

KW - Heparin

KW - NCCN Clinical Practice Guidelines

KW - Pulmonary embolism

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=33750049970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750049970&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2006.0071

DO - 10.6004/jnccn.2006.0071

M3 - Review article

C2 - 17020664

AN - SCOPUS:33750049970

SN - 1540-1405

VL - 4

SP - 838

EP - 869

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 9

ER -

Venous thromboembolic disease: Clinical practice guidelines in Oncology™

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this